On the stock market since 2013, it operates in the world of health and science. It has 161 employees. Now — the numbers.
The company closed last year at a loss: costs ran above sales. The picture changes only if spending is reined in.
An average decline of 41% a year over the last 4 years — the most striking risk in this picture. Red columns mark years that ended in a loss.
Before the clock runs out, either sales must climb sharply or new money must come in. This is the most critical line in the whole picture.
We compared this company with its own sector across five subjects.
A score of 50 means class average.
Clearly below the class average.
Clearly below the class average.
Clearly below the class average.
Clearly below the class average.
The stock has been running stronger than the market lately.
Business Quality: Profit power and business quality trail similar companies in the sector.
Financial Strength: The cash-and-debt balance is thin; the buffer for hard times is slim.
An investor who bought at the very peak is down 97% today. The business is the same; what changed most is the price — and the expectations — the market pins on it.
It met or beat analyst expectations in 8 of the last 8 quarters — consistency is a promise kept.
Over the last 12 months, company executives reported 28 buys and 13 sells. Management buying with its own money is usually read as a good sign.
The average analyst price target is $5.63 — 142% above today’s price.
A loss of $136.3M against $6.6M in annual sales. And on top of that, sales fell from the year before.
This stock swings about 2.5 times as much as the market average. Big rallies — and big drops — can both happen fast.
At the current pace of spending, the cash lasts about 1.5 years. After that, the company needs to find new money.
On our five-subject report card, FATE sits behind the class. A low grade doesn’t mean “doomed” — it means “big claim, small proof.”
The takeaway: FATE is a small company that closed last year at a loss. The road back to profit runs through spending discipline.
The total grade weighs these five subjects against the sector — it isn’t a simple average of the five.
Analysts’ average target sits above today’s price, yet the valuation grade (18/100) says the stock isn’t cheap.